BIOLOGICAL · Unmapped registry intervention
KYV-101 (Biological) - 0.33 ×10^8 cells
Find medicine records ·
Find other trials using this name
Clinical trial
A Study of KYV-101, a CD19 CAR T Cell Therapy, in Participants With Treatment Refractory Progressive Multiple Sclerosis
NCT06451159
Drugs and interventions used in this trial
4 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
BIOLOGICAL · Unmapped registry intervention
KYV-101 (Biological) - 1 ×10^8 cells
Find medicine records ·
Find other trials using this name
DRUG · Unmapped registry intervention
Chemotherapy: cyclophosphamide (CYC)
Find medicine records ·
Find other trials using this name
DRUG · Unmapped registry intervention
Chemotherapy: fludarabine (FLU)
Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedA Study of KYV-101, a CD19 CAR T Cell Therapy, in Participants With Treatment Refractory Progressive Multiple Sclerosis
Design: INTERVENTIONAL · Status: ACTIVE NOT RECRUITING · Phase: PHASE1
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Progressive Multiple Sclerosisunresolved
Interventions
Sponsors & collaborators
Bruce Creelead sponsor
Kyverna Therapeuticscollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT06451159 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.